Financial Performance - Net sales for the full year reached $12345 million, representing a 9.2% year-over-year growth[12] - Q2 2025 net sales were $3104 million, an 8.6% year-over-year increase[14] - Autoship customer sales for the full year totaled $10058 million, a 14.9% year-over-year increase[16] - Q2 2025 Autoship customer sales were $2577 million, up 14.9% year-over-year[18] - Net sales per active customer reached $591 in Q2 2025[10, 21] - Adjusted EBITDA for Q2 2025 was $183.3 million, with a 5.9% margin[10] - Free cash flow for Q2 2025 was $105.9 million[33] Customer Metrics - The company added 150,000 net new active customers sequentially[8] - Autoship customer sales accounted for 83.0% of net sales[10] - The company has 20.9 million active customers[21] Guidance - The company projects net sales of $3.07 billion to $3.10 billion for the third fiscal quarter of 2025, representing approximately 7% to 8% year-over-year growth[35] - The company anticipates adjusted diluted EPS of $0.28 to $0.33 for the third fiscal quarter of 2025[35] - The company forecasts net sales of $12.5 billion to $12.6 billion for the full fiscal year 2025[35] - The company expects an adjusted EBITDA margin of 5.4% to 5.7% for the full fiscal year 2025[35]

Encaleret & ADH1 Overview - Encaleret is an investigational oral calcilytic drug being developed as a potential treatment for Autosomal Dominant Hypocalcemia Type 1 (ADH1)[35, 38] - ADH1 is caused by activating variants in the CASR gene, leading to dysregulation of calcium homeostasis, decreased blood calcium, and increased urinary calcium[16, 17] - Diagnosis of ADH1 requires genetic testing, but is often delayed with a median age of 25 years[23, 24] - Conventional therapy for ADH1, including calcium and activated vitamin D, does not correct the underlying pathophysiology and may worsen long-term complications[17, 27] Clinical Development & Results - Phase 2 study of encaleret in 13 ADH1 patients showed rapid and sustained normalization of serum calcium, urine calcium, and PTH levels over 42 months[49, 56, 57] - In the Phase 2 study, 69% of participants responded to encaleret, achieving both blood and urine calcium in the target range at Week 24[59] - Encaleret was generally well-tolerated over 42 months of outpatient administration in the Phase 2 study, with most Treatment-Emergent Adverse Events (TEAEs) being mild[54] - The CALIBRATE Phase 3 study of encaleret in ADH1 is ongoing, with topline results expected in Fall 2025[62, 63] Market Opportunity - The estimated prevalent population of ADH1 in the US is approximately 12,000 individuals, with 73% being symptomatic[72] - ADH1 is emerging as the leading isolated cause of nonsurgical hypoparathyroidism, accounting for approximately 20% of all cases[76, 78] - The company projects peak year sales of encaleret to be over $1 billion, drawing a comparison to the XLH market[73]

Transforming GI Detection and Screening Our long-term, lifesaving vision is an ingestible capsule that, in a single, convenient, and noninvasive procedure, screens for multiple cancers— esophageal, gastric, pancreatic, liver, and colon—at early and still precancerous stages, using AI to analyze thousands of images captured in the GI tract. CapsoVision: Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" that reflect our current expectations and views ...

Porch Group Corporate Presentation September 2025 Copyright 2025 Porch Group, Inc. All rights reserved 241. 174. 0 highlight Disclaimers Financial Targets Porch is providing guidance and targets for future periods in this presentation based on current market conditions, assumptions, and expectations as of the date of this presentation. Actual results may vary due to a number of factors, and there is no guarantee that we will be able to achieve these results. Please refer to the below for important disclaime ...

Robot Consulting Co., Ltd. Nasdaq Ticker: LAWR Investor Presentation 1 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that reflect our current expectations and views of future events, all of which are subject to risks and uncertainties. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. You can find many (but not all) of these s ...

Corporate Strategy & Assets - Questerre holds strategic interests in Red Leaf for patented oil shale technology and a large oil resource in Utah[2] - The company is assessing a significant oil shale deposit in the Kingdom of Jordan for commercial development[2, 22] - Questerre is seeking value for a giant natural gas discovery in the St Lawrence Lowlands, Quebec[2, 27] - The company has a condensate-rich Montney resource play in Western Alberta with attractive economics and proven tight oil production in SE Saskatchewan/SW Manitoba[2] Financial & Operational Performance (Q2 2025) - Funds Flow from Operations reached $5 million[4] - Capital Expenditures amounted to $1 million[4] - The company reported a Working Capital Surplus of $13.2 million[4] - Production averaged 3,091 boe/d, with 55% weighting towards oil and liquids[4] - Revenue per boe was $48.62, with an Operating Netback of $21.90 per boe[4] Market Capitalization & Share Structure (Aug 31, 2025) - The Market Capitalization stood at $146 million[6] - Insiders held 24,099,804 shares, representing 6% of the total[6] - The Free Float was 404,416,032 shares, accounting for 94% of the total[6] - Daily Trading Volume averaged 1.6 million shares[6] Quebec Legal & Political Challenges - The company is seeking leave to appeal to the Supreme Court of Canada regarding the Quebec Court of Appeal decision on Bill 21[38] - Economic losses related to the Quebec situation are estimated to range between $700 million and $4.8 billion[38]

Climate Change Action Plan - South32 set a target to halve net operational emissions (Scope 1 and 2) by FY35, relative to FY21 levels[28] - The company expanded its net zero by 2050 goal to include Scope 3 emissions[28] - South32 sold Illawarra Metallurgical Coal (IMC), reducing transition risk and Scope 3 emissions[28] - The company converted two of Worsley Alumina's coal-fired boilers to natural gas as an interim step[28] Portfolio and Capital Expenditure - 51% of South32's FY25 Underlying EBITDA is from the Aluminium value chain[30] - 23% of South32's FY25 Underlying EBITDA is from Manganese[30] - 100% of South32's capital expenditure is directed towards transition materials[36] - Capital expenditure during CCAP 2022 (FY23 to FY25) was US$71 million[40] Emissions - Hillside Aluminium accounts for 58% of South32's operational emissions[45] - Worsley Alumina accounts for 16% of South32's operational emissions[45] - Mozal Aluminium accounts for 17% of South32's operational emissions[45] - Portfolio reshaping has contributed to an approximately 80% reduction in Scope 3 emissions[63]

Corporate Overview for Investors September 2025 Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding Synopsys, Inc.'s (Synopsys, we or our) short-term and long-term financial targets, expectations and objectives; our businesses, business segments, strategies, initiatives and opportunities, including, among other things, our plan to reallocate resources in our Design IP segment to higher growth opportunities; harness AI efficien ...

Earnings Supplement Q2 FY2026 September 9, 2025 1 Cautionary Notes Regarding Forward Looking Statements This document includes statements that are, or may be deemed to be, "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For all such statements, we claim the protection of the safe harbor for forward-looking statements provided by such sections and the Private Securities Litigation Ref ...

Investor Presentation Second Quarter Fiscal 2026 Copyright © Rubrik 2025 1 Copyright © Rubrik 2025 1 9-46-84 0-199-199 25-188-244 0-180-110 130-66-232 6-104-221 30-19-74 0-132-81 103-61-183 5-86-185 TEXT SECONDARY 0-149-149 4-129-186 0-100-100 18-58-123 102-221-221 117-216-248 153-233-233 117-216-248 PRIMARY 0-85-53 69-41-122 17-41-95 78-202-139 184-151-248 65-148-250 169-238-209 208-185-251 160-202-253 Important Notice and Disclaimers Forward-Looking Statements This press release and the related conference ...